1-20 of 95 Search Results for

*

Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers

Boris Guyot, Flora Clément, Youenn Drouet, Xenia Schmidt, Sylvain Lefort, Emmanuel Delay, Isabelle Treilleux, Jean-Philippe Foy, Sandrine Jeanpierre, Emilie Thomas, Janice Kielbassa, Laurie Tonon, Helen He Zhu, Pierre Saintigny, Wei-Qiang Gao, Arnaud de la Fouchardiere, Franck Tirode, Alain Viari, Jean-Yves Blay, Véronique Maguer-Satta
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1966–1980.
https://doi.org/10.1158/2767-9764.CRC-23-0196
Published: 29 September 2023
View article titled, An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers
Open the PDF for An Early Neoplasia Index (ENI10), Based on Molecular Identity of CD10 Cells and Associated Stemness Biomarkers, is a Predictor of Patient Outcome in Many Cancers in another window
Includes: Supplementary data
Journal Articles

Fusobacterium nucleatum Load Correlates with KRAS Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma

Koki Takeda, Minoru Koi, Yoshiki Okita, Sija Sajibu, Temitope O. Keku, John M. Carethers
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1940–1951.
https://doi.org/10.1158/2767-9764.CRC-23-0179
Published: 26 September 2023
View article titled, <em>Fusobacterium nucleatum</em> Load Correlates with <em>KRAS</em> Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma
Open the PDF for <em>Fusobacterium nucleatum</em> Load Correlates with <em>KRAS</em> Mutation and Sessile Serrated Pathogenesis in Colorectal Adenocarcinoma in another window
Includes: Supplementary data
Journal Articles

Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma

Mir Lim, Maishara Muquith, Bernadette Miramontes, Magdalena Espinoza, David Hsiehchen
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1912–1916.
https://doi.org/10.1158/2767-9764.CRC-23-0025
Published: 21 September 2023
View article titled, Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma
Open the PDF for Treatment Beyond Progression After Anti-PD-1 Blockade in Hepatocellular Carcinoma in another window
Journal Articles

The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC

Joanne B Weidhaas, Chen Hu, Ritsuko Komaki, Gregory A Masters, George R Blumenschein, Joe Y. Chang, Bo Lu, Adam P. Dicker, Jeffrey A Bogart, Yolanda I Garces, Samir Narayan, Clifford G. Robinson, Vivek S Kavadi, Joel S Greenberger, Christopher D Koprowski, James W. Welsh, Elizabeth Gore, Robert M MacRae, Rebecca Paulus, Jeffrey Bradley
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-23-0084
Published: 20 September 2023
View article titled, The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC
Open the PDF for The inherited KRAS-variant as a biomarker of Cetuximab Response in NSCLC in another window
Includes: Supplementary data
Journal Articles

Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project

Alexander Semaan, Vincent Bernard, Justin W Wong, Yuki Makino, Daniel B Swartzlander, Kimal I. Rajapakshe, Jaewon J Lee, Adam Officer, C. Max Schmidt, Howard H Wu, Courtney L Scaife, Kajsa Affolter, Daniela Nachmanson, Matthew A. Firpo, Michele Yip-Schneider, Andrew M. Lowy, Olivier Harismendy, Subrata Sen, Anirban Maitra, Yasminka A Jakubek, Paola A. Guerrero
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-22-0419
Published: 18 September 2023
View article titled, Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project
Open the PDF for Integrated Molecular Characterization of Intraductal Papillary Mucinous Neoplasms: An NCI Cancer Moonshot Precancer Atlas Pilot Project in another window
Includes: Supplementary data
Journal Articles

EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma

Shinya Sato, Masatoshi Nakagawa, Takeshi Terashima, Soichiro Morinaga, Yohei Miyagi, Eisaku Yoshida, Toru Yoshimura, Motoharu Seiki, Shuichi Kaneko, Makoto Ueno, Taro Yamashita, Naohiko Koshikawa
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1862–1874.
https://doi.org/10.1158/2767-9764.CRC-23-0087
Published: 15 September 2023
View article titled, EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma
Open the PDF for EphA2 Proteolytic Fragment as a Sensitive Diagnostic Biomarker for Very Early-stage Pancreatic Ductal Carcinoma in another window
Includes: Supplementary data
Journal Articles

Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer

Kanoko Katoh, Yuki Katoh, Akiko Kubo, Miho Iida, Yuji Ikeda, Takashi Iwata, Hiroshi Nishio, Masaki Sugawara, Daiki Kato, Makoto Suematsu, Shuichi Hirai, Kei Kawana
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1840–1852.
https://doi.org/10.1158/2767-9764.CRC-23-0138
Published: 13 September 2023
View article titled, Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer
Open the PDF for Serum Free Fatty Acid Changes Caused by High Expression of Stearoyl-CoA Desaturase 1 in Tumor Tissues Are Early Diagnostic Markers for Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer

M. Michael Dcona, Kranthi Kumar Chougoni, Diana T. Dcona, Jacqueline L West, Sahib J. Singh, Keith C. Ellis, Steven R. Grossman
Journal: Cancer Research Communications
Cancer Research Communications (2023)
https://doi.org/10.1158/2767-9764.CRC-22-0521
Published: 13 September 2023
View article titled, Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer
Open the PDF for Combined targeting of NAD biosynthesis and the NAD-dependent transcription factor C-terminal Binding Protein as a promising novel therapy for pancreatic cancer in another window
Includes: Supplementary data
Journal Articles

Blood Leukocyte AHRR Methylation and Risk of Non–smoking-associated Cancer: A Case-cohort Study of Non–Hodgkin Lymphoma

Christina Dahl, Ulla A. Hvidtfeldt, Anne Tjønneland, Per Guldberg, Ole Raaschou-Nielsen
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1781–1787.
https://doi.org/10.1158/2767-9764.CRC-23-0151
Published: 07 September 2023
View article titled, Blood Leukocyte <em>AHRR</em> Methylation and Risk of Non–smoking-associated Cancer: A Case-cohort Study of Non–Hodgkin Lymphoma
Open the PDF for Blood Leukocyte <em>AHRR</em> Methylation and Risk of Non–smoking-associated Cancer: A Case-cohort Study of Non–Hodgkin Lymphoma in another window
Journal Articles

PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction In Vitro and In Vivo

Lisa Marie Fröhlich, Heike Niessner, Birgit Sauer, Sofie Kämereit, Eftychia Chatziioannou, Simon Riel, Tobias Sinnberg, Birgit Schittek
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (9): 1743–1755.
https://doi.org/10.1158/2767-9764.CRC-23-0101
Published: 05 September 2023
View article titled, PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <em>In Vitro</em> and <em>In Vivo</em>
Open the PDF for PARP Inhibitors Effectively Reduce MAPK Inhibitor Resistant Melanoma Cell Growth and Synergize with MAPK Inhibitors through a Synthetic Lethal Interaction <em>In Vitro</em> and <em>In Vivo</em> in another window
Includes: Supplementary data
Journal Articles

Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer

Matjaz Rokavec, Elif Özcan, Jens Neumann, Heiko Hermeking
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1689–1700.
https://doi.org/10.1158/2767-9764.CRC-22-0489
Published: 30 August 2023
View article titled, Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer
Open the PDF for Development and Validation of a 15-gene Expression Signature with Superior Prognostic Ability in Stage II Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1662–1671.
https://doi.org/10.1158/2767-9764.CRC-23-0284
Published: 28 August 2023
View article titled, Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens
Open the PDF for Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens in another window
Includes: Supplementary data
Journal Articles

Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins

Junkai Wang, Alexander B. Saltzman, Eric J. Jaehnig, Jonathan T. Lei, Anna Malovannaya, Matthew V. Holt, Meggie N. Young, Mothaffar F. Rimawi, Foluso O. Ademuyiwa, Meenakshi Anurag, Beom-Jun Kim, Matthew J. Ellis
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1551–1563.
https://doi.org/10.1158/2767-9764.CRC-22-0501
Published: 15 August 2023
View article titled, Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins
Open the PDF for Kinase Inhibitor Pulldown Assay Identifies a Chemotherapy Response Signature in Triple-negative Breast Cancer Based on Purine-binding Proteins in another window
Includes: Supplementary data
Journal Articles

Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer

Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis, Panagiota Economopoulou, Ioannis Kotsantis, Maria Gkotzamanidou, Maria Anastasiou, Dimitrios Pectasides, Efthymios Kyrodimos, Alexander Delides, Evangelos Giotakis, Nikolaos G. Papadimitriou, Ioannis G. Panayiotides, Christos Perisanidis, Aileen I. Fernandez, Vasiliki Xirou, Christos Poulios, Eleni Gagari, Vesal Yaghoobi, Niki Gavrielatou, Saba Shafi, Thazin Nwe Aung, Andromachi Kougioumtzopoulou, Vassilis Kouloulias, Konstantinos Palialexis, Stavros Gkolfinopoulos, Areti Strati, Evi Lianidou, George Fountzilas, David L. Rimm, Periklis G. Foukas, Amanda Psyrri
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1514–1523.
https://doi.org/10.1158/2767-9764.CRC-23-0051
Published: 10 August 2023
View article titled, Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer
Open the PDF for Phase II Window Study of Olaparib Alone or with Cisplatin or Durvalumab in Operable Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids

Oliver J. Pickles, Kasun Wanigasooriya, Anetta Ptasinska, Akshay J. Patel, Helen L. Robbins, Claire Bryer, Celina M. Whalley, Louise Tee, Neeraj Lal, Claudia M.A. Pinna, Nahla Elzefzafy, Philippe Taniere, Andrew D. Beggs, Gary M. Middleton
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1501–1513.
https://doi.org/10.1158/2767-9764.CRC-23-0091
Published: 09 August 2023
View article titled, MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids
Open the PDF for MHC Class II is Induced by IFNγ and Follows Three Distinct Patterns of Expression in Colorectal Cancer Organoids in another window
Includes: Supplementary data
Journal Articles

The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer

Lucie Van Emmenis, Sheng-Yu Ku, Kaitlyn Gayvert, Jonathan R. Branch, Nicholas J. Brady, Subhasree Basu, Michael Russell, Joanna Cyrta, Aram Vosoughi, Verena Sailer, Hussein Alnajar, Etienne Dardenne, Elena Koumis, Loredana Puca, Brian D. Robinson, Michael D. Feldkamp, Annmarie Winkis, Nathan Majewski, Brent Rupnow, Marco M. Gottardis, Olivier Elemento, Mark A. Rubin, Himisha Beltran, David S. Rickman
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1447–1459.
https://doi.org/10.1158/2767-9764.CRC-22-0491
Published: 03 August 2023
View article titled, The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer
Open the PDF for The Identification of CELSR3 and Other Potential Cell Surface Targets in Neuroendocrine Prostate Cancer in another window
Includes: Supplementary data
Journal Articles

Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma

Holly A. Hill, Preetesh Jain, Chi Young Ok, Koji Sasaki, Han Chen, Michael L. Wang, Ken Chen
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1435–1446.
https://doi.org/10.1158/2767-9764.CRC-23-0083
Published: 02 August 2023
View article titled, Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma
Open the PDF for Integrative Prognostic Machine Learning Models in Mantle Cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression

Cara C. Schafer, Jiji Jiang, Sally Elsamanoudi, Darryl Nousome, Denise Y. Young, Yingjie Song, Isabell A. Sesterhenn, Gregory T. Chesnut, Shyh-Han Tan
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (8): 1423–1434.
https://doi.org/10.1158/2767-9764.CRC-22-0463
Published: 01 August 2023
View article titled, Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression
Open the PDF for Immunologic Assessment of Tumors from a Race-matched Military Cohort Identifies Mast Cell Depletion as a Marker of Prostate Cancer Progression in another window
Includes: Supplementary data
Journal Articles

Integrated Multi-omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness

Maria-Fernanda Senosain, Yong Zou, Khushbu Patel, Shilin Zhao, Alexis Coullomb, Dianna J. Rowe, Jonathan M. Lehman, Jonathan M. Irish, Fabien Maldonado, Michael N. Kammer, Vera Pancaldi, Carlos F. Lopez
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1350–1365.
https://doi.org/10.1158/2767-9764.CRC-22-0373
Published: 26 July 2023
View article titled, Integrated Multi-omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness
Open the PDF for Integrated Multi-omics Analysis of Early Lung Adenocarcinoma Links Tumor Biological Features with Predicted Indolence or Aggressiveness in another window
Includes: Supplementary data
Journal Articles

Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment

Beom-Jun Kim, Ze-Yi Zheng, Jonathan T. Lei, Matthew V. Holt, Anran Chen, Jianheng Peng, Diana Fandino, Purba Singh, Hilda Kennedy, Yongchao Dou, María del Rosario Chica-Parrado, Emmanuel Bikorimana, Dan Ye, Yunguan Wang, Ariella B. Hanker, Nada Mohamed, Susan G. Hilsenbeck, Bora Lim, Jaya Ruth Asirvatham, Arun Sreekumar, Bing Zhang, George Miles, Meenakshi Anurag, Matthew J. Ellis, Eric C. Chang
Journal: Cancer Research Communications
Cancer Research Communications (2023) 3 (7): 1366–1377.
https://doi.org/10.1158/2767-9764.CRC-23-0044
Published: 26 July 2023
View article titled, Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment
Open the PDF for Proteogenomic Approaches for the Identification of NF1/Neurofibromin-depleted Estrogen Receptor–positive Breast Cancers for Targeted Treatment in another window
Includes: Supplementary data